Zoryve is under clinical development by Arcutis Biotherapeutics and currently in Pre-Registration for Psoriasis.

The application of PDE4 inhibitors appears to be a promising option to facilitate with minimal side effects the spontaneous passage of (distal) ureteral stones and relieve pain associated with ...

Spain: A multicenter observational study has highlighted the potential of oral roflumilast, a phosphodiesterase-4 (PDE4) ...

Discovered and characterized at The University of North Carolina at Chapel Hill, the compound showed potent PDE4D inhibition and demonstrated high selectivity over other PDE families.

There's already stiff competition in the oral psoriasis category, however, from drugs with different mechanisms of action, including Amgen's PDE4 inhibitor Otezla (apremilast) – already making ...

Preliminary pharmacokinetics data from the first cohorts demonstrated delayed release of the PDE4 inhibitor active suggesting PALI-2108 is performing as designed with colonic bioactivation.

INR:1225. in football how many players are there Pfizer's PDE4 inhibitors approved; five overseas new drugs urgently needed ...

INR:5427. 100 rupees carrom board PDE4 inhibitor urgently needed in clinical practice is being marketed in China. Amgen acquires the company for $13.4 bil ...

About PALI-2108 PALI-2108 is an orally administered, locally acting colon-specific PDE4 inhibitor prodrug in development for patients affected by UC. The Company continued to progress development ...

ZORYVE cream 0.15% is the first once-daily, Food and Drug Administration (FDA)-approved topical treatment for mild to moderate atopic dermatitis ZORYVE, a next-generation topical phosphodiesterase-4 ...

ZORYVE cream 0.15% is the first once-daily, Food and Drug Administration (FDA)-approved topical treatment for mild to moderate atopic dermatitis ZORYVE, a next-generation topical phosphodiesterase-4 ...